Loading…
← CockpitCompetitor Analysis › ABCL AbCellera Biologics, Inc.Open in the cockpit ↗

AbCellera Biologics, Inc.ABCLCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Uses AI and lab automation to discover antibodies for pharma partners and its own drug pipeline.

≈ A discovery-stage biotech, like Moderna but for antibodies rather than mRNAMomentum leader 97
Mkt cap
$3.60B
US dollars, full cap
Free float
78%
of shares outstanding
$/day
$36.6M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-52.0 pp
WACC 12.8%
Hurdle
n/a
no reverse DCF
Next earnings
97 days
23 Feb 2027
Close · USD$11.02
1D-0.1%
1W-7.8%
1M-5.9%
3M-4.8%
6M+141.1%
YTD+222.2%
1Y+206.1%
ATR %7.9%
Beta2.37
52w lowhigh26.6% off high

What AbCellera Biologics does

Uses AI and lab automation to discover antibodies for pharma partners and its own drug pipeline.

Earns research fees, milestones and royalties from partners that use its platform to find antibodies, and invests in its own drug candidates. Its income spiked in 2021 on royalties from the COVID antibody it helped find for Lilly, and has since come from smaller partner programmes while it builds its own pipeline.

In one line: A discovery-stage biotech, like Moderna but for antibodies rather than mRNA.

Products and services

  • Antibody discovery platform (partnered)
  • Internal pipeline (oncology, immunology)

Customers

  • Pharma/biotech partners including Eli Lilly
  • Government pandemic-response programs

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Antibody discovery platform

What could go right

  • Partner program milestone and royalty payments
  • Internal pipeline progression

What could go wrong

  • Dependence on partner program success
  • Cash burn from platform buildout

Moat: narrow (data, IP / patents, process know-how). Large proprietary antibody discovery database and high-throughput screening platform.

Headquarters: Vancouver, Canada · Founded: 2012 · Employees: 562

Named competitors

AbCellera Biologics at a glance

Size AbCellera Biologics (ABCL) is a United States Health Care company (Biotechnology) with a market value of $3.60B, the 1407th largest of 3,085 United States companies the cockpit tracks. Shares closed at $11.02 on 18 Nov 2026.

Performance Over six months the shares gained 141.1%, against -2.0% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 21 in its peer set.

Growth Revenue grew 92.1% over the last twelve months (peer median +8.3%); the operating margin is -298.0% (peer median -0.7%).

Valuation It trades at 43.4× enterprise value to sales against a peer median of 8.7× (5th most expensive of 16).

Capital Return on invested capital runs 52.0 points below its cost of capital (12.8% WACC).

Backlog Backlog (remaining performance obligations) was $56.0M at 30 Jun 2026. Backlog detail →

Short interest Short interest is 9.0% of the free float (30 Oct 2026).

Next results Next results expected around 23 Feb 2027 (exchange calendar; dates can move).

Relative performance

10020030021 May 202621 Aug 202618 Nov 2026ABCL 214Peer median 98
Six months, rebased to 100: AbCellera Biologics against the median of its 20 peers (local-currency closes).

AbCellera Biologics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$67.9M$75.1M$28.8M$38.0M$485M
Revenue growth—+161%-24%-92%—
Gross profit$33.9M$46.3M-$68.2M$7.13Mn/a
EBITDA-$168M-$188M-$218M-$206M$316M
Net income-$148M-$146M-$163M-$146M$159M
Free cash flow-$31.3M-$174M-$187M-$121M$207M
Capital expenditure$16.9M$42.8M$78.4M$77.5M$72.7M
Total debt$134M$143M$65.4M$77.4M$82.3M

Quarterly statements and history in the cockpit →

AbCellera Biologics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%+150%-20%0%+20%IRONRLAY603127TNGX600161IOVA6919CRSPELVN6696002007VIRPXERS603392ADMATLXDNLIRUBICONABCL6-month return →1-month return →
Up and to the right = strong over both horizons. AbCellera Biologics is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%+100%0×2,000×4,000×6,000×RLAY603127600161IOVA6919CRSP002007VIRPXERS1530TLXABCLRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. AbCellera Biologics is the large dot.

AbCellera Biologics competitors and peer comparison

Head to head with its named competitors (ABCL vs TWST vs ABSI vs OABI)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
AbCellera Biologics ABCL$3.60B+141%+92%-298%43.4×n/a
Twist Bioscience TWST$7.93B+117%+22%-29%16.2×n/a
Absci ABSI$1.41B+65%-47%-9,155%835.7×n/a
OmniAb OABI$741M+97%+91%-116%17.3×60.6%
Evotec EVT.DE$532M-46%-5%-15%0.8×n/a
Charles River Laboratories CRL$16.0B+114%-1%15%4.7×25.6%
Genscript Biotech 1548.HK$8.69B+133%+53%12%9.8×36.9%

How AbCellera Biologics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

AbCellera Biologics against its 20 peers (data as of 18 Nov 2026)
MeasureABCLPeer medianRank in peer set
1-month return-5.9%-5.1%11th highest of 21
6-month return+141.1%-2.0%3rd highest of 21
Distance from 52-week high-26.6%-32.6%7th highest of 21
Revenue growth (TTM)+92.1%+8.3%2nd highest of 16
Operating margin-298.0%-0.7%5th lowest of 16
EV / Sales43.4×8.7×5th most expensive of 16
ROIC minus cost of capital-52.0 pp-6.2 pp2nd lowest of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
AbCellera Biologics ABCLUnited States$3.60B+141%+92%-298%43.4×n/an/a
Disc Medicine IRONUnited States$3.55B+16%n/an/an/an/an/a
Relay Therapeutics RLAYUnited States$3.65B+27%+24%-3,095%273.1×n/an/a
Joinn Laboratories (China) 603127.SSChina$3.67B-6%+12%-4%11.8×n/an/a
Tango Therapeutics TNGXUnited States$3.71B+4%-100%n/an/an/an/a
Beijing Tiantan Biological Products 600161.SSChina$3.47B-13%-13%21%4.5×2.2%+12.5%
Iovance Biotherapeutics IOVAUnited States$3.46B+111%+51%-61%8.3×n/an/a
Caliway Biopharmaceuticals 6919.TWTaiwan$3.32B-25%-54%-6,983%6,626.2×n/an/a
CRISPR Therapeutics CRSPUnited States$3.90B-17%-34%-2,059%95.6×n/an/a
Enliven Therapeutics ELVNUnited States$3.30B+7%n/an/an/an/an/a
Lin BioScience 6696.TWOTaiwan$3.98B+305%n/an/an/an/an/a
Hualan Biological Engineering 002007.SZChina$3.20B-17%-11%17%5.3×15.8%-1.8%
Virbac VIRP.PAFrance$3.20B-4%+4%15%2.1×5.8%+9.4%
Xeris Biopharma XERSUnited States$3.10B+173%+38%13%8.7×29.5%+70.2%
Beijing Wantai Biological Pharmacy Enterprise 603392.SSChina$4.20B-43%+8%-35%12.7×n/an/a
3SBio 1530.HKHong Kong$4.28B-31%+102%61%0.9×n/an/a
ADMA Biologics ADMAUnited States$3.01B+58%+6%45%6.0×-0.8%+64.6%
Telix Pharmaceuticals TLX.AXAustralia$2.99B-2%+27%-1%3.8×n/an/a
Dyne Therapeutics DYNUnited States$2.97B-10%n/an/an/an/an/a
Denali Therapeutics DNLIUnited States$2.95B-2%n/a-2,488%115.4×n/an/a
Rubicon Research RUBICON.NSIndia$2.94B+68%+37%21%13.2×n/an/a

AbCellera Biologics backlog

AbCellera Biologics reported $56.0M of remaining performance obligations at 30 Jun 2026.

Questions

Who are AbCellera Biologics's main competitors?
Named competitors: Twist Bioscience (TWST), Absci (ABSI), Adimab (private or unlisted), OmniAb (OABI), Evotec (EVT.DE), Charles River Laboratories (CRL). The cockpit's measured peer set (industry) also includes Disc Medicine (IRON), Relay Therapeutics (RLAY), Joinn Laboratories (China) (603127.SS), Tango Therapeutics (TNGX), Beijing Tiantan Biological Products (600161.SS), Iovance Biotherapeutics (IOVA).
Is AbCellera Biologics expensive compared with its peers?
On ev / sales it trades at 43.4× against a peer median of 8.7×, 5th most expensive of 16 in its peer set.
How has AbCellera Biologics stock performed?
Over six months to 18 Nov 2026 the shares returned +141.1% against -2.0% for the median peer; over one year +206.1%.
What is AbCellera Biologics's backlog?
AbCellera Biologics's remaining performance obligations (contracted revenue not yet recognised) were $56.0M at 30 Jun 2026.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.